Positive data for Novartis's potential first-in-class psoriasis drug AIN457
This article was originally published in Scrip
Novartis has unveiled the first set of positive Phase II psoriasis data for its novel interleukin (IL)-17 inhibitor, AIN457 (secukinumab), at the European Academy of Dermatology and Venereology (EADV) meeting on 24 October. AIN457 is now undergoing mammoth Phase III trials, and as the most clinically advanced IL-17 inhibitor, and Datamonitor believes it has potential to be first in class should it continue to show strong efficacy and no new safety signals.
You may also be interested in...
Leading dermatologists have published a new meta-analysis of safety data in psoriasis.